In vitro activities of PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite against Mycobacterium avium complex.
PS-15, a new dihydrofolate reductase inhibitor, and its cyclic metabolite were evaluated for in vitro activity against 31 clinical Mycobacterium avium complex isolates. Broth dilution MICs of PS-15 ranged from 16 to 64 micrograms/ml. The cyclic metabolite was three to five times more active than the parent compound. Further evaluation of these compounds in an M. avium-infected murine test system will be of interest.
D000962:Antimalarials / Q000494:pharmacology; D003500:Cyclization; D003622:Dapsone / Q000494:pharmacology; D005493:Folic Acid Antagonists / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D015269:Mycobacterium avium Complex / Q000187:drug effects*; D002727:Proguanil / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology
D000962:Antimalarials; D005493:Folic Acid Antagonists; D014227:Triazines; C082651:PS 15; C006201:BRL 6231; D003622:Dapsone; D002727:Proguanil